emoxypine succinate

has antihypoxic effects

Also Known As:

2-ethyl-6-methyl-3-hydroxypyridine succinate; 3-pyridinol, 2-ethyl-6-methyl-, butanedioate (1:1) (salt); butanedioic acid, compd. with 2-ethyl-6-methyl-3-pyridinol (1:1); methylethylpiridinol succinate; mexidol; mexiprim

Networked: 215 relevant articles (44 outcomes, 52 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Picolines: 14
      - emoxypine succinate: 215

Experts

1.	Volchegorskiĭ, I A: 17 articles (01/2014 - 01/2005)
2.	Rassokhina, L M: 14 articles (01/2017 - 01/2008)
3.	Voronina, T A: 11 articles (01/2020 - 01/2002)
4.	Iasnetsov, V V: 8 articles (11/2012 - 01/2000)
5.	Miroshnichenko, I Iu: 7 articles (01/2014 - 03/2009)
6.	Miroshnichenko, I Yu: 5 articles (01/2017 - 01/2011)
7.	Volchegorskii, I A: 5 articles (01/2017 - 01/2011)
8.	Gan'shina, T S: 5 articles (01/2016 - 10/2010)
9.	Kalugina, A V: 5 articles (04/2015 - 01/2014)
10.	Chukanova, E I: 4 articles (01/2021 - 01/2015)

Related Diseases

1.	Brain Ischemia (Cerebral Ischemia) 01/01/2021 - "[The efficacy and safety study of Mexidol and Mexidol FORTE 250 in patients with chronic cerebral ischemia]." 01/01/2019 - "[The study of the efficacy and safety of Mexidol and Mexidol Forte 250 in patients with chronic cerebral ischemia]." 01/01/2015 - "[The results of the study of the efficacy and safety of mexidol in patients with chronic cerebral ischemia]." 01/01/2020 - "[Results of the sequential use of Mexidol and Mexidol Forte 250 in patients with chronic cerebral ischemia]." 01/01/2016 - "The results indicate the multi-component multi-level stress-limiting effect of mexidol in patients with chronic cerebral ischemia stage II. Цель исследования. "
2.	Ischemic Stroke 01/01/2020 - "Consecutive treatment with mexidol and mexidol forte 250 in the acute and early recovery periods of ischemic stroke positively affects the regression of local neurological symptoms, increases the likelihood of achieving independence in everyday life by 3,34 times, and reduces the severity of optical-spatial, neurodynamic and memory impairments. " 01/01/2013 - "Efficacy of mexiprim in the correction of the revealed psychoautonomic problems in patients with ischemic stroke is shown. " 01/01/2020 - "[Efficacy and safety of mexidol across age groups in the acute and early recovery stages of hemispheric ischemic stroke (results of additional sub-analysis of a randomized double blind multicenter placebo-controlled study, in parallel groups trial EPICA)]." 01/01/2019 - "To study rheological properties of blood in patients with acute ischemic stroke treated with mexidol. " 01/01/2015 - "To study the efficacy and safety of early use of mexidol in the acute stage of severe ischemic stroke (IS). "
3.	Stroke (Strokes) 01/01/2011 - "The effect of neglect and push syndromes on the results of rehabilitation in stroke patients and efficacy of mexidol in their removal were studied as well. " 01/01/2011 - "To evaluate efficacy of mexidol in the rehabilitative treatment of patients with stroke, treatment results of 440 patients were analyzed. " 01/01/2022 - "[Study of the efficacy and safety of sequential use of the drugs Mexidol and Mexidol FORTE 250 in the treatment of stroke]." 01/01/2020 - "Early management (in the first 6 hours) with mexidol significantly improve recovery dynamic and stroke outcome. " 01/01/2012 - "[Effects of mexidol on the functional state of the central nervous system in post-stroke patients]."
4.	Open-Angle Glaucoma (Glaucoma, Open Angle) 01/01/2023 - "The drug Mexidol has a wide range of pharmacological activity and affects the main pathogenetic links of primary open-angle glaucoma (POAG). " 03/01/2013 - "Purpose was to study efficiency and safety of mexidol in combined therapy in patients with primary open-angle glaucoma (POAG). " 01/01/2022 - "The results of studies demonstrate that Mexidol is effective in slowing down neurodegeneration and stabilizing visual functions in patients with primary open-angle glaucoma due to its antihypoxic, antioxidant and membrane-stabilizing properties, as well as its positive impact on the neuromediator balance and ocular blood flow. " 07/01/2012 - "The prospective single-blind placebo-controlled randomized trial is devoted to influence of mexidol (2-ethil-6-methil-3-hydroxipiridine succinate) on dynamics of optic nerve electrophysiologic profile and velocity indices of blood flow in ocular and orbital arteries in correlation with changes of retinal photosensitivity, visual acuity and visual field size during course of intravenous mexidol infusions and standard treatment of primary open-angle glaucoma. " 07/01/2012 - "[The influence of water soluble antioxidant agent (mexidol) on optic nerve and blood flow velocity in ocular and orbital arteries in patients with primary open-angle glaucoma]."
5.	Asthenia 01/01/2022 - "Mexidol administration improved cognitive functions, decreased the level of asthenia, depressia, improved sleep disturbances, and normalized biochemical landscape. " 01/01/2014 - "A comparative analysis of the patient's condition in both groups has demonstrated a reduction in symptoms of asthenia, autonomic lability and cognitive deficit in patients treated with mexidol." 01/01/2022 - "The results of trial showed that in patients of different age-subgroups with chronic brain ischemia the improvement in cognitive, motor impairment and quality of life, as well as decrease in vegetative impairment, asthenia and anxiety are observed after 75 days of treatment both in Mexidol and placebo group, but in Mexidol group these changes are more prominent. "

Related Drugs and Biologics

1.	Antioxidants
2.	6-methyl-2-ethyl-3-hydroxypyridine
3.	Succinic Acid (Succinate)
4.	Tablets
5.	ethylmethylhydroxypyridine succinate
6.	cortexin
7.	cerebrolysin
8.	Escin
9.	Lipids
10.	Neuroprotective Agents

Related Therapies and Procedures

1.	Therapeutics
2.	Secondary Prevention
3.	Vascular Surgical Procedures
4.	Hyperbaric Oxygenation
5.	Carotid Endarterectomy